Revolutionizing Small Cell Lung Cancer Treatment
Practical webinars, case studies, and clinical guides from Dana-Farber experts on delivering bispecific T-cell engager therapy safely and effectively.
Learn from a Multidisciplinary Thoracic Oncology Team
Jacob Sands, MD
Physician
Associate Chair of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute.
Dr. Sands leads the small cell lung cancer program at the Dana-Farber Cancer Institute and is an Assistant Professor at Harvard Medical School. He earned his medical degree from the University of Cincinnati and completed his residency and fellowship at UC Davis. He serves on several committees, including the NCCN guidelines committee for lung screening and small cell lung cancer. Dr. Sands leads multiple clinical trials and is a scientific board member for GO2 for Lung Cancer.
Stephanie McDonald, MSN, FNP-BC, AOCNP
Nurse Practitioner
Nurse Practitioner in the Thoracic Oncology Program at Dana-Farber Cancer Institute.
Stephanie specializes in small cell lung cancer (SCLC) and thoracic malignancies. Stephanie is recognized for her expertise in oncology nursing and immunotherapy. She collaborates with multidisciplinary teams to create personalized treatment plans, manage side effects, and educate and support patients and families. Stephanie is involved in research and education, presenting at conferences and publishing in journals like the Journal of Cancer Research and Clinical Oncology. She recently co-authored a nurse resource guide on Bispecific T Cell Engagers in solid tumors, demonstrating her commitment to advancing oncology nursing and improving patient outcomes.
Leila Rostamnjad, PharmD, BCOP
Pharmacist
Leila (LAY-luh) Rostamnjad (ros-TAHM-nejad), PHARMD, BCOP, is a clinical Pharmacy Manager in Solid Tumors and Thoracic Oncology and a symptoms management specialist at Dana-Farber Cancer Institute. In her role, she is involved in drug onboarding, the development of institutional guidelines and policies, and the creation of educational materials for pharmacy staff, nurses, and patients.
Kara Stocks, PA-C
Physician Assistant
Kara Stocks is an Associate Chief Physician Assistant within the inpatient solid tumor oncology program at Dana-Farber/Brigham and Women’s Cancer Center. She received her undergraduate degree in Health Sciences at Northeastern University and completed her Master’s in Physician Assistant studies at Pace University- Lenox Hill Hospital. Kara joined Dana-Farber in 2017 as a member of the inpatient oncology team. She was an inaugural member of the Immunotherapy Toxicity team and has since become involved in inpatient implementation of clinical trials as well as safe administration of inpatient chemotherapy and other therapies.
Michelle Dupille, RN, BSN, OCN
Nurse
Michelle Dupille is a Certified Oncology Nurse with over 20 years of experience across inpatient, outpatient, and home care settings. She currently serves as a Nurse Navigator in the Thoracic Oncology Program at Dana-Farber Cancer Institute, where she is deeply committed to guiding and supporting patients through their cancer journey. Drawing on her extensive clinical knowledge and critical thinking skills, Michelle collaborates closely with the care team to ensure high-quality, patient-centered care. She maintains her oncology certification and actively engages in continuing education and nursing conferences to stay current with the latest evidence-based practices in oncology care.
Eileen Arnone
Patient
Eileen lives in Massachusetts with her husband. She has three grown children, and her grandchildren live nearby. Eileen worked in business credit management until her retirement. She enjoys cooking, seeing dear friends, and celebrating milestones with her family.
Watch the Webinar: Team-Based Implementation of Bispecific Therapy
See it in Practice: Case Study
BE READI: Short Videos on Bispecific Therapy Practice
Downloadable Guides for Your Clinic
Bispecific Agents in Solid Tumors: Nurse Resource Guide
A practical reference for nurses caring for patients on bispecific therapy.
Practical Management of Adverse Events with Tarlatamab
Sands et al., 2024. Expert guidance on recognizing and managing treatment-related side effects in previously treated SCLC.
For People Affected by Small Cell Lung Cancer
If you or someone you love is facing SCLC, you don’t have to navigate it alone. GO2 for Lung Cancer offers free education and support designed for patients and families.
Free SCLC Educational Materials
Browse free patient education from the GO2 store
GO2 SCLC Support Programs
Support and resources for people affected by SCLC
SCLC Explained
A short animated overview of what SCLC is, how it’s staged and how GO2 can help
Sponsored by Amgen. GO2 for Lung Cancer retains final editorial control over the educational content. Views expressed by individual speakers are their own.
This site is intended for healthcare professionals
I am a healthcare professional
I am a patient or caregiver